Capital International Inc. CA Acquires 16,108 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Capital International Inc. CA increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 191,341 shares of the pharmaceutical company’s stock after purchasing an additional 16,108 shares during the period. Capital International Inc. CA’s holdings in Vertex Pharmaceuticals were worth $74,937,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of VRTX. Chesapeake Asset Management LLC raised its position in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 33 shares in the last quarter. Colonial Trust Co SC raised its position in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares in the last quarter. Total Investment Management Inc. bought a new stake in Vertex Pharmaceuticals during the second quarter worth about $33,000. Financial Network Wealth Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 50.9% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 29 shares in the last quarter. Finally, Y.D. More Investments Ltd increased its position in shares of Vertex Pharmaceuticals by 345.0% during the 3rd quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 69 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Amit Sachdev sold 58,613 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the completion of the transaction, the executive vice president owned 58,934 shares of the company’s stock, valued at approximately $27,630,027.22. This represents a 49.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the sale, the executive vice president owned 17,559 shares in the company, valued at $8,562,646.35. This represents a 21.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 91,156 shares of company stock worth $42,845,497. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ VRTX opened at $460.87 on Tuesday. The firm has a fifty day simple moving average of $467.50 and a two-hundred day simple moving average of $435.79. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The firm has a market capitalization of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. During the same quarter in the prior year, the firm earned $3.98 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER Phase 3 interim analysis met the primary endpoint and all secondary endpoints at Week 36, with treated patients showing the intended benefit versus placebo — a major validation step for povetacicept in IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results (BusinessWire)
• Positive Sentiment: Management plans an FDA filing for povetacicept by March, accelerating the regulatory timeline and shortening the path to potential commercialization if final data and review go smoothly. Vertex Stock Surges After Positive Kidney Disease Trial Results (Blockonomi)
• Positive Sentiment: Analysts have reiterated and strengthened bullish views — William Blair’s Myles Minter reiterated a Buy and highlighted increased confidence in povetacicept’s commercial potential, supporting upside to consensus models. Analyst Confidence Boosts Buy Thesis (TipRanks)
• Positive Sentiment: Market reaction: shares rallied in extended trading after the release; coverage notes the asset was acquired in a prior multibillion-dollar deal and is viewed as having “best‑in‑class” potential in a competitive kidney disease market. Vertex Kidney Drug Hits Mark in Late-Stage Study (BioPharmaDive)
• Neutral Sentiment: The result cited is an interim analysis of an ongoing trial — final RAINIER readout, full safety dataset, and regulatory review still lie ahead, so approval and peak sales remain subject to execution and FDA assessment. Press Release / Interim Analysis Details (Yahoo Finance)

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Oppenheimer raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price target on the stock in a research note on Friday, February 13th. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Royal Bank Of Canada decreased their price objective on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Barclays raised their price target on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 17th. Finally, Wolfe Research raised Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective for the company in a research note on Tuesday, January 6th. Twenty-two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.